Evidence-Based Medicine Guidelines
SGLT-2 inhibitors in type 2 diabetes
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"SGLT-2 Inhibitors in Type 2 Diabetes." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305247/all/SGLT_2_inhibitors_in_type_2_diabetes.
SGLT-2 inhibitors in type 2 diabetes. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305247/all/SGLT_2_inhibitors_in_type_2_diabetes. Accessed March 28, 2025.
SGLT-2 inhibitors in type 2 diabetes. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305247/all/SGLT_2_inhibitors_in_type_2_diabetes
SGLT-2 Inhibitors in Type 2 Diabetes [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 March 28]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305247/all/SGLT_2_inhibitors_in_type_2_diabetes.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - SGLT-2 inhibitors in type 2 diabetes
ID - 1305247
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305247/all/SGLT_2_inhibitors_in_type_2_diabetes
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
